title: A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.
abstract: The effect of the selective serotonin reuptake inhibitor (SSRI) sertraline 200 mg/day on the metabolism of intravenously administered tolbutamide was examined in a randomised nonblinded parallel-group study in 25 healthy male volunteers. There was a small but statistically significant decrease (16%) in the clearance of tolbutamide in patients receiving the maximum recommended dosage of sertraline. The terminal elimination rate constant was also significantly reduced, corresponding to the increase in the terminal elimination half-life (from 6.9 to 8.6 hours). The decrease in clearance was not associated with any significant changes in plasma protein binding or in the apparent volume of distribution of tolbutamide. This suggests that the change in tolbutamide clearance may be due to a slight inhibition of the cytochrome P450 (CYP) isoenzyme CYP2C9/10 when sertraline was administered in its maximum recommended dosage. However, the small changes in the volume of distribution and plasma binding of tolbutamide after sertraline treatment indicate that there is a minimal interaction between sertraline and tolbutamide.
authors.affiliation: Pfizer Central Research, Groton, Connecticut, USA.
authors.forename: L M
authors.initials: LM
authors.lastname: Tremaine
authors.forename: K D
authors.initials: KD
authors.lastname: Wilner
authors.forename: S H
authors.initials: SH
authors.lastname: Preskorn
mesh_terms: D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases; D001798:Blood Proteins / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D065607:Cytochrome P-450 Enzyme Inhibitors; D004357:Drug Synergism; D006801:Humans; D007004:Hypoglycemic Agents / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D011485:Protein Binding; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors; D014044:Tolbutamide / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D015057:1-Naphthylamine; D000928:Antidepressive Agents; D001189:Aryl Hydrocarbon Hydroxylases; D001798:Blood Proteins; D065729:Cytochrome P-450 CYP2C9; D065607:Cytochrome P-450 Enzyme Inhibitors; D007004:Hypoglycemic Agents; D006899:Mixed Function Oxygenases; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases; D014044:Tolbutamide; C450260:CYP2C9 protein, human